DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Market Access (2711)

Formulary Advantages in Immune Biologic Therapies: Health plans’ support for certain drug attributes drive formulary coverage for immune biologic brands

Formulary Advantages in Immune Biologic Therapies: Health plans’ support for certain drug attributes drive formulary coverage for immune biologic brands

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The market for immune biologics has grown increasingly crowded in recent years with the launches of newer brands such as Simponi, Cimzia, and Stelara looking to take share away from longer-marketed products such as the TNF-alpha inhibitors Enbrel and Humira, as well as Remicade. Despite some of the advantages of newer therapies, commercial and Medicare plans continue to favor longer-marketed products that have known efficacy and safety/tolerability track records. Tiering data from Fingertip Formulary show that health plans have increased their advantaged tier coverage (Tier 1 or 2 placement) for some of these newer therapies in the past year, but plans continue to offer the best tier positions to the longer-marketed brands. Importantly, surveyed health plans report that increased spending on prescription drugs for rheumatoid arthritis, Crohn's disease, and psoriasis over the past five years have not resulted in flat or lower costs for non-drug (i.e., medical) expenses. This finding suggests that plans are not seeing the desired results for greater prescription drug costs and may make them more interested in TNF-alpha inhibitors and drugs that feature an alternative mechanism of action (MOA) that can reduce medical costs. 26% of surveyed plans report that they favor a single TNF-alpha inhibitor brand for treating RA, and they are split between Enbrel and Humira. A survey of pharmacy directors resulted in similar findings for therapies with an alternative MOA.

  • Pub Date: June 2011

Purchase Report

Recent reports:
You may also be interested in: